Expertise in
2
conditions

Dr. Bruce J. Averbook

Surgical Oncology
The MetroHealth System
2500 Metrohealth Dr, 
Cleveland, OH 
Accepting New Patients
Expertise in
2
conditions
The MetroHealth System
2500 Metrohealth Dr, 
Cleveland, OH 

Overview

Bruce Averbook is a Surgical Oncologist practicing medicine in Cleveland, Ohio.

Dr. Averbook is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Melanoma, Merkel Cell Carcinoma, Neuroendocrine Tumor, Tissue Biopsy, and Endoscopy.

He is actively involved in clinical research, co-authoring 7 peer reviewed articles and participating in 66 clinical trials. Dr. Averbook is currently accepting new patients.

Specialties

Surgical Oncology

Licenses

Surgery in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

CareSource
  • HMO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

The MetroHealth System
2500 Metrohealth Dr, Cleveland, OH 44109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

66 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
A Randomized Phase III Study of Immune Checkpoint Inhibition With Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Biological, Drug
Study Drugs: Carboplatin, Nivolumab, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

7 Total Publications

Staging breast cancer by sentinel lymph node biopsy: Do patients with a single negative sentinel node (N=1) experience worse outcomes than those with multiple negative sentinel nodes (N>1)?
Staging breast cancer by sentinel lymph node biopsy: Do patients with a single negative sentinel node (N=1) experience worse outcomes than those with multiple negative sentinel nodes (N>1)?
Journal: Surgical oncology
Published: February 21, 2018
Similar Doctors
Expertise in
16
conditions
Dr. Jordan M. Winter
Surgical Oncology | General Surgery
Expertise in
16
conditions
Dr. Jordan M. Winter
Surgical Oncology | General Surgery
Referral may be required

University Hospitals

11100 Euclid Ave, 
Cleveland, OH 
 (5.7 miles away)
216-844-5777
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jordan Winter is a Surgical Oncologist and a General Surgeon practicing medicine in Cleveland, Ohio. Dr. Winter is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, Pancreatectomy, and Pancreaticoduodenectomy. Dr. Winter is currently accepting new patients.

Expertise in
10
conditions
Dr. Julie E. Lang
Surgical Oncology
Expertise in
10
conditions
Dr. Julie E. Lang
Surgical Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
 (4.9 miles away)
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients

Julie Lang is a Surgical Oncologist practicing medicine in Cleveland, Ohio. Dr. Lang is highly rated in 10 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Inflammatory Breast Cancer, Intraductal Papilloma, HER-2 Positive Breast Cancer, and Lymphadenectomy. Dr. Lang is board certified in American Board Of Surgery, 2006. Dr. Lang is currently accepting new patients.

Expertise in
10
conditions
Dr. Chad M. Michener
Surgical Oncology
Expertise in
10
conditions
Dr. Chad M. Michener
Surgical Oncology
Referral may be required
Before you request

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
 (5.1 miles away)
866-223-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chad Michener is a Surgical Oncologist practicing medicine in Cleveland, Ohio. Dr. Michener is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Eccrine Porocarcinoma, Melanoma, Desmoplastic Small Round Cell Tumor, Endoscopy, and Hernia Surgery. Dr. Michener is board certified in American Board Of Obstetrics And Gynecology, 2008. Dr. Michener is currently accepting new patients.

Frequently Asked Questions about Dr. Bruce J. Averbook

How do I make an appointment with Dr. Bruce J. Averbook?

You can book an appointment with Dr. Bruce J. Averbook by calling their office at 216-778-7800. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bruce J. Averbook a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bruce J. Averbook is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bruce J. Averbook specialize in?

While Dr. Bruce J. Averbook is a Surgical Oncology, they have specific expertise in Melanoma, Merkel Cell Carcinoma, and Neuroendocrine Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Surgical Oncology.

Does Dr. Bruce J. Averbook participate in research or clinical trials?

Yes. Dr. Bruce J. Averbook has published 7 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Bruce J. Averbook's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bruce J. Averbook accept my insurance?

Dr. Bruce J. Averbook accepts most major insurance plans, including CareSource and Humana. We recommend calling the office directly at 216-778-7800 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Averbook's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile